Support of Central Spinal Fluid Biomarker Study–ADNI


Cure Alzheimer’s Fund is part of a funding consortium supporting collaborative biomarker investigation of the elevation of tau and decreased concentrations of Amyloid beta 42 in the Central Spinal Fluid as evidence of the presence of the Alzheimer’s disease pathology.


Biomarkers/Diagnostics/Studies of Risk & Resilience, Foundational


John Q. Trojanowski, M.D., Ph.D.

Leslie M. Shaw, Ph.D.